Gene structure, promoter activity, and chromosomal location of the DR-nm23 gene, a related member of the nm23 gene family

Cancer Res. 1997 Mar 15;57(6):1180-7.

Abstract

DR-nm23 cDNA was cloned recently by differential screening of a cDNA library derived from chronic myelogenous leukemia-blast crisis primary cells. It is highly homologous to the putative metastasis suppressor nm23-H1 gene and the closely related nm23-H2 gene. When overexpressed in the myeloid precursor 32Dcl3 cell line, it inhibited granulocyte colony-stimulating factor-stimulated granulocytic differentiation and induced apoptosis. We have now found that the expression of DR-nm23 is not restricted to hematopoietic cells but is also detected in an array of solid tumor cell lines, including carcinoma of the breast, colon, and prostate, as well as the glioblastoma cell line T98G. We have also isolated both the gene and its 5'-flanking region and found that DR-nm23 localizes on chromosome 16q13. The gene consists of six exons and five introns. When fused in-frame to the nucleotide sequence for the green fluorescent protein and transfected in SAOS-2 cells, it generates a protein of the predicted size that localizes to the cytoplasm. The 5'-flanking region of DR-nm23 does not contain a canonical TATA box or a CAAT box, but it is G+C rich and contains two binding sites for the developmentally regulated transcription factor activator protein 2 (AP-2). Transient expression assays of DR-nm23 promoter-chloramphenicol acetyltransferase constructs demonstrated that the segment from nucleotides -1028 to +123 has the highest activity in hematopoietic K562 cells and in TK-ts13 hamster fibroblasts. Moreover, AP-2 induced a 3-fold transactivation of the DR-nm23 5'-flanking segment from nucleotides -1676 to +123 and interacted specifically with oligomers containing putative AP-2 binding sites (-936 to -909, and -548 to -519) as indicated by electrophoretic mobility shift assay. Furthermore, nuclear run-on assays from high and low DR-nm23-expressing cells (K562 and CCRF-CEM, respectively) revealed similar transcription rates. Therefore, the regulation of the DR-nm23 gene expression might involve other mechanisms occurring at posttranscriptional and/or translational levels.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Base Sequence
  • Blast Crisis / genetics
  • Blast Crisis / pathology
  • Chromosome Mapping
  • Chromosomes, Human, Pair 16 / genetics*
  • Cloning, Molecular
  • Cricetinae
  • DNA, Complementary / genetics
  • DNA, Neoplasm / genetics
  • Genes
  • Hematologic Neoplasms / genetics
  • Hematologic Neoplasms / metabolism
  • Hematologic Neoplasms / pathology
  • Humans
  • Hybrid Cells
  • Leukemia, Myeloid, Accelerated Phase / genetics
  • Leukemia, Myeloid, Accelerated Phase / pathology
  • Molecular Sequence Data
  • Monomeric GTP-Binding Proteins*
  • Multigene Family*
  • NM23 Nucleoside Diphosphate Kinases
  • Neoplasm Proteins / biosynthesis
  • Neoplasm Proteins / genetics
  • Neoplasm Proteins / physiology
  • Neoplasms / genetics
  • Neoplasms / metabolism
  • Neoplasms / pathology
  • Nucleoside-Diphosphate Kinase*
  • Promoter Regions, Genetic
  • Recombinant Fusion Proteins / biosynthesis
  • Sequence Homology, Nucleic Acid
  • Transcription Factors / genetics*
  • Transcription, Genetic
  • Transfection
  • Tumor Cells, Cultured

Substances

  • DNA, Complementary
  • DNA, Neoplasm
  • NM23 Nucleoside Diphosphate Kinases
  • Neoplasm Proteins
  • Recombinant Fusion Proteins
  • Transcription Factors
  • NME1 protein, human
  • Nucleoside-Diphosphate Kinase
  • Monomeric GTP-Binding Proteins

Associated data

  • GENBANK/U80813